GAVI and its partners identified and published a shortlist of vaccines that should be prioritized to transform global immunization — and Micron’s needle-free measles rubella vaccine ranks on the top of that list.
Thank you, Linda Geddes and Gavi, the Vaccine Alliance for featuring Micron Biomedical and describing the critical need for new vaccine delivery technologies to increase vaccine coverage globally. We are honored to be recognized among the top innovators in this space and committed to breaking barriers to vaccine and therapeutic access at home and abroad.
See the below excerpts and read the full article here to learn why needle-free technology is poised to revolutionize global vaccine access: https://lnkd.in/gv-CTaX8
“We are hoping that this measles-rubella vaccine will be a trailblazer, and once we will have manufacturing proof of concept for this one, the level of interest and investment in other vaccine microarray patches in the pipeline will increase, accelerating their development.”
“In some cases, such as for measles, MAPs are considered essential to be able to reach global and regional elimination targets – and are likely to be needed more than ever in the current environment of vaccine hesitancy.”
Menu